Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)

Lung Cancer Clinical Trial

Official title:

Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06219174
• Other study ID #: MCC-20386
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: December 18, 2023
• Est. completion date: December 2028

Study information

• Verified date: March 2024
• Source: H. Lee Moffitt Cancer Center and Research Institute
• Contact: Anahid Aminpour
• Phone: 813-745-0287
• Email: Anahid.Aminpour[@]moffitt.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to establish the safety, toxicity, and tolerability of Difluoromethylornithine (DFMO) in combination with pembrolizumab in advanced/metastatic Non-Small Cell Lung Cancer (NSCLC). Researchers also want to investigate how effective DFMO is at treating patients with advanced/ metastatic NSCLC.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 45
• Est. completion date: December 2028
• Est. primary completion date: December 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients must be willing and able to provide written informed consent/assent for the trial.

• Patients must be = 18 years of age on day of signing informed consent.

• Patients must have measurable disease based on RECIST 1.1

• Patients must have archival tissue where available. Patients enrolled on the phase 1 escalation trial where archival tissue is not available will undergo a fresh biopsy where clinically feasible after discussion with the sponsor.

• Patients enrolled on the Phase II trial must be willing and able to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion.

• Tumor proportional score of PD-L1 =1%

• Patients must have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.

• Patients must demonstrate adequate organ function on all screening labs. Screening labs should be performed within 10 days of treatment initiation.

• Patients must have a histologic or cytologic diagnosis of Stage IV NSCLC.

• Patients must harbor an STK11 mutation via CLIA-certified assay.

• Phase I: Patients may have progression from at least one prior line of therapy.

• Phase II: Patients must be treatment naïve in the stage IV setting, with the exception of patients whose tumors harbor an activating mutation (including but not limited to EGFR, ALK, ROS1) and were previously treated with targeted therapy.

• Female patients of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication.

• Female patients of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication.

• Male patients should agree to use an adequate method of barrier contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.

• Patients cannot have clinically significant hearing loss that requires a hearing aid.

Exclusion Criteria:

• Patients who are currently participating in and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.

• Patients that have a diagnosis of immunodeficiency or is receiving systemic steroid therapy at doses = 10 mg prednisone or any other form of systemic immunosuppressive therapy within 7 days prior to the first dose of trial treatment.

• Patients that have a known history of TB Disease (Mycobacterium tuberculosis).

• Patients that have a hypersensitivity to pembrolizumab, DFMO or any of its excipients.

• Patients enrolled on the phase II trial, who have had prior treatment with a PD1 or PDL1 inhibitor, anti-CTLA 4 antibody or any other antibody or drug that specifically targets immune checkpoint pathway in the stage IV setting (i.e. not "immune therapy naïve").

• Patients who have received thoracic radiation >30Gy within six months of the first dose of pembrolizumab.

• Patients that had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., = Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.

• Patients that have received major surgery must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.

• Patients that have a known additional malignancy that is progressing or requires active treatment.

Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer.

• Patients that have a known active central nervous system (CNS) metastasis and/or carcinomatous meningitis.

• Patients that have active autoimmune disease that has required systemic treatment in the past 2 years.

• Patients that have an active infection requiring systemic therapy.

• Patients that have a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, that would substantially increase risk of incurring adverse events (AEs) from the study medications, that would interfere with the subject's participation for the full duration of the trial or is not in the best interest of the subject to participate, in the opinion of the treating investigator.

• Patients that have a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the trial.

• Patients that have a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).

• Patients that have known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).

• Patients that have received a live vaccine within 30 days of planned start of study therapy.

• Patients that have a history of, or any evidence of active non-infectious pneumonitis that required or requires steriods.

• Patients that have evidence of interstitial lung disease (ILD).

• Patients that have a history of symptomatic (NYHA class II-IV) heart failure.

• Patients harboring STK11 variants listed in ClinVAR as benign or likely-benign will be excluded from this study.

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms
• Non Small Cell Lung Cancer

Intervention

Drug:
• Pembrolizumab
200 mg IV Q3 weeks
• Difluoromethylornithine
Dose Level -1: 4500 mg/m2 by mouth (PO) daily Dose Level 1: 6750 mg/m2 by mouth (PO) daily Dose Level 2: 9000 mg/m2 by mouth (PO) daily

Locations

Country	Name	City	State
United States	Moffitt Cancer Center	Tampa	Florida

Sponsors (1)

Lead Sponsor	Collaborator
H. Lee Moffitt Cancer Center and Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase I- Maximum Tolerated Dose (MTD)	To determine the maximum tolerated dose (MTD) and recommended phase II dose (R2PD) of DFMO in combination with pembrolizumab. The MTD will be declared if 1 or fewer patients have a Dose limiting toxicity (DLT) in that dose level.	Up to 12 Months
Primary	Phase II- Objective Response Rate (ORR)	To determine the efficacy of DFMO in combination with pembrolizumab. Objective response is defined as confirmed complete response (CR) or confirmed partial response (PR) based on modified RECIST guidelines version 1.1.	Up to 5 Years
Secondary	Phase II- Progression Free Survival (PFS)	Progression-free survival will be measured from the start of treatment with pembrolizumab and DFMO until the documentation of disease progression or death due to any cause, whichever occurs first. For subjects who are alive and progression-free at the time of data cut-off for analysis, PFS will be censored at the last tumor assessment date.	Up to 5 Years
Secondary	Phase II- Overall Survival (OS)	Overall survival will be determined as the time from the start of treatment with pembrolizumab and DFMO until death due to any cause. For subjects who are alive at the time of data cut-off, OS will be censored on the last date when subjects are known to be alive.	Up to 5 Years

External Links

•   Moffitt Cancer Center's Clinical Trials Website